David M. Albala, MD, presented “The Live Primary Cell Phenotypic Test (LPCP) for Prostate Cancer” during the 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 3, 2019 in Boston, Massachusetts.

How to cite: Albala, David M. “The Live Primary Cell Phenotypic Test (LPCP) for Prostate Cancer” October 3, 2019. Accessed Sep 2020. https://grandroundsinurology.com/the-live-primary-cell-phenotypic-test-lpcp/

The Live Primary Cell Phenotypic Test (LPCP) for Prostate Cancer – Summary:

David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York, discusses the experimental live primary cell phenotypic test (LPCP) for prostate cancer. He details how live, unfixed cancer cells are taken from tissue, plated out on an extracellular matrix, and grown in a single cell monolayer. The LPCP looks at 14 different biomarkers from both normal and malignant cells, and machine learning algorithms generate scores that, according to preliminary research, can accurately predict general, local, and metastatic adverse pathology potential.

About The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer:

The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a multi-day, multi-disciplinary forum designated to informing health care stakeholders about topics including in-vitro fluid- and tissue-based molecular diagnostics, novel observation strategies such as active surveillance, and novel therapeutic interventions. Along with this forum’s efforts to form a consensus on the future of prostate diagnostics and precision care, it aims to create an educational and research strategy for its realization. Dr. Albala presented this lecture during the 4th iteration of this Summit in 2019.